Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib
复制标题
DOI：
10.1001/archderm.144.6.779
复制
发表时间：
2008-06-01
影响因子：
--
通讯作者：
Kurzrock, Razelle
中科院分区：
文献类型：
--
作者：
Hong, David S.;Reddy, Srini B.;Kurzrock, Razelle
背景资料：角化棘皮瘤，以及光化性角化病进展为鳞状细胞癌，已报告的患者谁被治疗索拉非尼，已知抑制Raf激酶和血管内皮生长因子receptor.Observations的行动的多激酶抑制剂：我们描述了一个70岁的白色妇女与转移性肾细胞癌谁被治疗索拉非尼和tipifarnib（法尼基转移酶抑制剂）的组合。她没有皮肤癌病史。然而，在开始这种治疗后的3个月内，她的腿上出现了3个结节。病理检查显示为浸润性深、分化良好的鳞状细胞癌。切除肿瘤，并停止索拉非尼-替吡法尼治疗。没有新的病变已经发展到data.Conclusions：靶向药物，如索拉非尼和替吡法尼，越来越多地被用于内脏恶性肿瘤的管理。在靶向治疗的开始和这些皮肤癌的出现之间观察到时间关系。对这种情况下鳞状细胞癌快速出现的机制的进一步研究可能会对皮肤肿瘤的发病机制提供见解。
Background: Keratoacanthomas, as well as an actinic keratosis progressing to squamous cell cancer, have been reported in patients who were treated with sorafenib, a multikinase inhibitor known to suppress the actions of Raf kinase and vascular endothelial growth factor receptor.Observations: We describe a 70-year-old white woman with metastatic renal cell carcinoma who was treated with a combination of sorafenib and tipifarnib (a farnesyltransferase inhibitor). She had no history of skin cancer. However, within 3 months after starting this therapy, she developed 3 erythematous nodules on her legs. Pathologic examination showed deeply invasive, well-differentiated squamous cell carcinomas. The tumors were excised, and sorafenib-tipifarnib treatment was discontinued. No new lesions have developed to date.Conclusions: Targeted agents, such as sorafenib and tipifarnib, are increasingly being used in the management of visceral malignant neoplasms. A temporal relationship was observed between the initiation of the targeted treatments and the emergence of these cutaneous cancers. Further study of the mechanisms responsible for the rapid appearance of squamous cell cancers in this setting may provide insights into the pathogenesis of skin tumors.